ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) Free cash flow 2017–2025
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$48.9MFY2025 · since FY2017: -$37.3M → -$48.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$48.9M | +50.5% |
| FY2024 | -$98.9M | +40.8% |
| FY2023 | -$167.0M | +16.6% |
| FY2022 | -$200.3M | +21.3% |
| FY2021 | -$254.5M | -51.0% |
| FY2020 | -$168.5M | -186.8% |
| FY2019 | $194.2M | +603.7% |
| FY2018 | -$38.6M | -3.4% |
| FY2017 | -$37.3M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More ADPT financial trends
ADPT RevenueADPT Net incomeADPT Net marginADPT Gross profitADPT Gross marginADPT Operating incomeADPT Operating marginADPT Operating cash flowADPT Capital expendituresADPT Return on equityADPT Stock buybacksADPT Dividends paidADPT Total assetsADPT Total liabilitiesADPT Shareholders’ equityADPT overview →